Cytovation Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6M
- Investors
-
3
Cytovation General Information
Description
Developer of a synthetic peptide designed to provide treatment for benign tumors and various types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action that guides the immune system to recognize and eradicate tumors, enabling patients to get treatment for cutaneous warts and malignant cancers.
Contact Information
Website
www.cytovation.comCorporate Office
- Solheimsgaten 11
- 5058 Bergen
- Norway
Corporate Office
- Solheimsgaten 11
- 5058 Bergen
- Norway
Cytovation Timeline
Cytovation Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 23-Apr-2025 | $6M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series A) | 02-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series 1) | 01-Jan-2019 | $3.63M | Completed | Clinical Trials - Phase 1 | ||
| 1. Angel (individual) | 08-Jan-2018 | $3.63M | $3.63M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cytovation Patents
Cytovation Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202413516-D0 | Treatment of cancers associated with beta-catenin | Inactive | 13-Sep-2024 | ||
| AU-2024351102-A1 | Treatment of cancers associated with beta-catenin | Pending | 26-Sep-2023 | ||
| EP-4784151-A1 | Treatment of cancers associated with beta-catenin | Pending | 26-Sep-2023 | ||
| GB-202314749-D0 | Treatment of cancers associated with beta-catenin | Inactive | 26-Sep-2023 | ||
| WO-2025068426-A1 | Treatment of cancers associated with beta-catenin | Inactive | 26-Sep-2023 | A61K38/1709 |
Cytovation Signals
Cytovation Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Additio Investment Group | Venture Capital | Minority | ||
| Canica | PE/Buyout | Minority | ||
| Sandwater | Venture Capital | Minority |
Cytovation FAQs
-
When was Cytovation founded?
Cytovation was founded in 2001.
-
Where is Cytovation headquartered?
Cytovation is headquartered in Bergen, Norway.
-
What is the size of Cytovation?
Cytovation has 10 total employees.
-
What industry is Cytovation in?
Cytovation’s primary industry is Drug Discovery.
-
Is Cytovation a private or public company?
Cytovation is a Private company.
-
What is Cytovation’s current revenue?
The current revenue for Cytovation is .
-
How much funding has Cytovation raised over time?
Cytovation has raised $37.6M.
-
Who are Cytovation’s investors?
Additio Investment Group, Canica, and Sandwater have invested in Cytovation.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process